peHUB -- diaDexus Inc., a South San Francisco-based developer of a blood test for the prediction of cardiovascular disease, has raised around $9.2 million in Series F funding, according to a regulatory filing. Listed shareholders include Scale Venture Partners, GlaxoSmithKline and Baker Brothers Advisors.
